Cargando…

Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis

BACKGROUND: Pleural mesothelioma (PM) is a relatively rare malignancy with limited treatment options and dismal prognosis. We have previously found elevated FGF18 expression in PM tissue specimens compared with normal mesothelium. The objective of the current study was to further explore the role of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mosleh, Berta, Schelch, Karin, Mohr, Thomas, Klikovits, Thomas, Wagner, Christina, Ratzinger, Lukas, Dong, Yawen, Sinn, Katharina, Ries, Alexander, Berger, Walter, Grasl‐Kraupp, Bettina, Hoetzenecker, Konrad, Laszlo, Viktoria, Dome, Balazs, Hegedus, Balazs, Jakopovic, Marko, Hoda, Mir Alireza, Grusch, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396789/ https://www.ncbi.nlm.nih.gov/pubmed/37340889 http://dx.doi.org/10.1111/1759-7714.15004

Ejemplares similares

Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
por: Vlacic, Gregor, et al.
Publicado: (2019)

Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin
por: Ries, Alexander, et al.
Publicado: (2023)

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
por: Brcic, Luka, et al.
Publicado: (2021)

FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo
por: Ghassemi, Sara, et al.
Publicado: (2017)

Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow
por: Kovacs, Ildiko, et al.
Publicado: (2022)

Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection
por: Sinn, Katharina, et al.
Publicado: (2022)

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
por: Laszlo, Viktoria, et al.
Publicado: (2018)

Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
por: Klikovits, Thomas, et al.
Publicado: (2017)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014)

Primary and hTERT-Transduced Mesothelioma-Associated Fibroblasts but Not Primary or hTERT-Transduced Mesothelial Cells Stimulate Growth of Human Mesothelioma Cells
por: Ries, Alexander, et al.
Publicado: (2023)

Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells
por: Hoda, M A, et al.
Publicado: (2012)

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma
por: Hoda, Mir Alireza, et al.
Publicado: (2016)

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study
por: Ghanim, B, et al.
Publicado: (2015)

Corrigendum to ‘Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study’: [ESMO Open Volume 7, Issue 2, April 2022, 100466]
por: Sinn, K., et al.
Publicado: (2022)

Interaction of FGF9 with FGFR3‐IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma
por: Paur, Jakob, et al.
Publicado: (2020)

Apelin promotes lymphangiogenesis and lymph node metastasis
por: Berta, Judit, et al.
Publicado: (2014)

Erythropoietin Receptor Expression Is a Potential Prognostic Factor in Human Lung Adenocarcinoma
por: Rózsás, Anita, et al.
Publicado: (2013)

Multicellular contractility contributes to the emergence of mesothelioma nodules
por: Tarnoki-Zach, Julia, et al.
Publicado: (2020)

Management of malignant pleural mesothelioma – part 3: Data from the Austrian Mesothelioma Interest Group (AMIG) database
por: Klikovits, Thomas, et al.
Publicado: (2016)

YB-1 Knockdown Inhibits the Proliferation of Mesothelioma Cells through Multiple Mechanisms
por: Johnson, Thomas G., et al.
Publicado: (2020)

Management of malignant pleural mesothelioma – part 1: epidemiology, diagnosis, and staging: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
por: Geltner, Christian, et al.
Publicado: (2016)

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
por: Ghimessy, Áron Kristof, et al.
Publicado: (2019)

Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer
por: Lang, C., et al.
Publicado: (2022)

Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
por: Solta, Anna, et al.
Publicado: (2023)

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors
por: Torok, Szilvia, et al.
Publicado: (2017)

FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer
por: Harpain, Felix, et al.
Publicado: (2018)

Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
por: Sinn, K., et al.
Publicado: (2022)

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
por: Molnár, Eszter, et al.
Publicado: (2018)

Lymph Node Log-Odds Ratio Accurately Defines Prognosis in Resectable Non-Small Cell Lung Cancer
por: Benej, Michal, et al.
Publicado: (2023)

Management of malignant pleural mesothelioma—part 2: therapeutic approaches: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
por: Hoda, Mir Alireza, et al.
Publicado: (2016)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

The landscape of small cell lung cancer metastases: Organ specificity and timing
por: Megyesfalvi, Zsolt, et al.
Publicado: (2021)

Stromal Expression of Heat-Shock Protein 27 Is Associated with Worse Clinical Outcome in Patients with Colorectal Cancer Lung Metastases
por: Schweiger, Thomas, et al.
Publicado: (2015)

A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
por: Schelch, Karin, et al.
Publicado: (2017)

A comparison of sample preparation strategies for biological tissues and subsequent trace element analysis using LA-ICP-MS
por: Bonta, Maximilian, et al.
Publicado: (2016)

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
por: Borchert, Sabrina, et al.
Publicado: (2020)

Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC)
por: Lohinai, Zoltan, et al.
Publicado: (2016)

Bone-Specific Metastasis Pattern of Advanced-Stage Lung Adenocarcinoma According to the Localization of the Primary Tumor
por: Radeczky, Peter, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n9joo3brkl7055efbtvqfesqlt